Related Experiment Video
Updated: Feb 9, 2026
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Left atrial appendage occlusion with lambre in atrial fibrillation: Initial European experience
Jai-Wun Park1, Horst Sievert2, Caroline Kleinecke3
1Medical Clinic II (Cardiology/Intensive Care Medicine), Klinikum Coburg, Coburg, Germany; Department of Cardiology, Charité Berlin - University Medicine, Campus Benjamin Franklin, Berlin, Germany.
Insights
The LAmbre left atrial appendage occluder demonstrated high success in European patients with atrial fibrillation, showing effective stroke and bleeding prevention over mid-term follow-up.
Area of Science:
- Cardiology
- Medical Devices
- Interventional Cardiology
Background:
- The LAmbre is a novel, self-expanding left atrial appendage (LAA) occluder.
- First European experience with the LAmbre device is reported.
Purpose of the Study:
- To evaluate the safety and efficacy of the LAmbre device for LAA occlusion.
- To assess the mid-term performance of LAAO in patients with atrial fibrillation and contraindications to oral anticoagulation.
Main Methods:
- Sixty patients with atrial fibrillation underwent LAA occlusion using the LAmbre device at two German centers.
- Device success, complications, LAA sealing, and clinical outcomes were assessed.
Main Results:
- 100% device success was achieved, with 94.4% complete LAA sealing at 6 months.
- Complications included 3.3% pericardial effusions requiring pericardiocentesis.
- At 12 months, 1.6% experienced transient ischemic attack and 5% had minor bleeding.
Conclusions:
- LAAO with the LAmbre device shows high device success and good mid-term efficacy in preventing stroke and bleeding.
- Minimizing procedure-related complications remains an area for improvement.
Background:
We here report the first European experience with the novel LAmbre left atrial appendage (LAA) occluder, a self-expanding device consisting of an umbrella and a cover connected by a central waist.
Methods And Results:
A total of 60 patients (74.4 ± 8.3 years; 66.7% men; CHA2DS2-VASc: 4.0 ± 1.6, HAS-BLED score: 3.2 ± 1.3) with atrial fibrillation and contraindications to oral anticoagulation underwent left atrial appendage occlusion (LAAO) with the LAmbre device at two German centers between November 2013 and September 2015. Device success defined as correct placement of the device was achieved in all patients (100%). Resizing of the device was necessary in 3 (5%) patients. Device-related complications included 2 (3.3%) pericardial effusions on day 8 and 33 after the index procedure requiring pericardiocentesis. Transesophageal echocardiography at 6 months showed complete sealing of the LAA (residual jet flow of <5 mm) in 51/54 (94.4%) patients. No device-related thrombus was documented. At 12 months transient ischemic attack was observed in 1 patient (1.6%) and minor bleeding in 3 patients (5%).
Conclusions:
Although minimizing procedure-related complications remains challenging, LAAO with the LAmbre showed high device success and good mid-term performance regarding prevention of stroke and bleeding.
Related Concept Videos
01:25ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
03:03Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
03:03Amyloid Fibrils
02:33Initiation of Translation
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
02:33Initiation of Translation
01:23Surface Appendages of Archaea